Combined sodium-glucose-transporters inhibitors (SGLT2i) and glucagon-like-peptide receptor agonist (GLP1ra) compared with SGLT2i or GLP1ra alone improves survival: a Real-World Registry

30 August 2024 (08:00 - 17:30)

Organised by:

Sign in for access options

Sign in to view the resources

Sign in for access options

About the speaker

Doctor David Garcia Vega

Ourense University Hospital Complex, Ourense (Spain)

3 More presentations in this session

Presentation thumbnail

State-of-the-art lecture on repurposing of diabetic medications: the new cure for all evils?

Associate Professor A. Navar (Dallas, US)

Presentation thumbnail

Impact of SGLT2 inhibitors on liver-related outcomes in patients with heart failure - a population-based study in HK

Ms H. Yang (Hong Kong, HK)

Abstract Slides Video

Presentation thumbnail

Risk of Incident colorectal carcinoma in patients with type 2 diabetes on SGLT-2 inhibitor users: a population-based cohort study

Doctor G. Jong (Taichung, TW)

Abstract Slides Video

Access the full session

Session thumbnail

Repurposing anti-diabetic pharmacotherapy: the new cure for all evils?

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024

You may be interested in

Congress Presentation

Combined therapy of SGLT2i and GLP1ra reduces all-cause mortality in patients with type 2 diabetes with a higher impact on women

Congress Presentation

The effect of Glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in type 2 diabetes mellitus patients with coronary artery disease

Congress Presentation

Glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter-2 inhibitors combination therapy after acute myocardial infarction in patients with type 2 diabetes mellitus: a dynamic duo

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources